Loading...
•
Dec 31, 2024
AbbVie Q4 2024 Earnings Report
AbbVie's Q4 2024 financial results were reported, showing revenue increase and mixed performance across different portfolios.
Key Takeaways
AbbVie reported a 5.6% increase in net revenues for Q4 2024, reaching $15.102 billion. The company's adjusted diluted EPS was $2.16, which includes an unfavorable impact of $0.88 related to acquired IPR&D and milestones expense. While some portfolios like Neuroscience and Oncology experienced growth, others like Aesthetics saw a decrease. The company provides 2025 adjusted diluted EPS guidance range of $12.12 to $12.32.
Worldwide net revenues increased by 5.6% to $15.102 billion.
Adjusted diluted EPS was $2.16, impacted by acquired IPR&D and milestones expense.
Immunology portfolio net revenues increased by 4.9% to $7.294 billion, driven by Skyrizi and Rinvoq.
Neuroscience portfolio net revenues increased by 19.8% to $2.509 billion, led by Botox Therapeutic and Vraylar.
AbbVie
AbbVie
AbbVie Revenue by Segment
AbbVie Revenue by Geographic Location
Revenue by Segment
Immunology Revenue
CapyFin.comNeuroscience Revenue
CapyFin.comOncology Revenue
CapyFin.comAesthetics Revenue
CapyFin.comEye Care Revenue
CapyFin.comOther Key Products Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
AbbVie provided its adjusted diluted EPS guidance for the full-year 2025 of $12.12 to $12.32. The company reaffirms expectations for a high single-digit compound annual revenue growth rate through 2029. AbbVie is raising its long-term outlook for Skyrizi and Rinvoq revenues and now expects combined Skyrizi and Rinvoq 2027 revenues of more than $31 billion. AbbVie is also updating its outlook for aesthetics revenues and now expects a high single-digit compound annual revenue growth rate for aesthetics through 2029.
Positive Outlook
- Adjusted diluted EPS guidance for full-year 2025 is $12.12 to $12.32.
- Reaffirms expectations for high single-digit compound annual revenue growth rate through 2029.
- Combined Skyrizi and Rinvoq 2027 revenues are expected to be more than $31 billion.
- Skyrizi revenues of more than $20 billion in 2027 are expected.
- Aesthetics revenues are expected to have a high single-digit compound annual revenue growth rate through 2029.
Challenges Ahead
- 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones.
- Long-term guidance assumes 2024 as the base year in the compound annual growth rate calculation.
- Aesthetics revenue growth rate assumes 2025 as the base year in the compound annual growth rate calculation.
- Diluted loss per share in the fourth quarter was $0.02 on a GAAP basis, inclusive of the recent partial intangible asset impairment charge related to emraclidine.
- Results include an unfavorable impact of $0.88 per share related to acquired IPR&D and milestones expense.
Revenue & Expenses
Visualization of income flow from segment revenue to net income